Top Message

The Miraca Group operates in the healthcare sector, with a focus on clinical diagnostics and laboratory tests in the pursuit of our corporate philosophy of helping to create a healthy and prosperous society and promoting global healthcare through the provision of novel and value-added products and services.

As its core business, the Miraca Group offers a comprehensive clinical laboratory testing service, which involves collecting and testing biological specimens (patient blood or urine) from medical institutions, and reporting the results of tests. The Group also specializes in the development, manufacture, and commercialization of in vitro diagnostic reagents indispensable to clinical testing through its affiliates in Japan and overseas. Moreover, the Group is involved in other healthcare related businesses such as clinical trial-related services to support pharmaceutical research and development, as well as sterilization-outsourcing services of reusable medical and surgical instruments in hospitals.

In Japan, it is anticipated that needs for healthcare services will diversify and grow with the rapidly aging society and advances in medical technologies. New medical care and services are required to respond to these trends. In this environment, clinical tests are essential, not only for the diagnosis and treatment of diseases but also for disease prevention. There are also growing demands for greater efficiency in the operation and management of hospitals. Healthcare is likely to be increasingly outsourced, with the contract testing and sterilization business playing a much more significant role.

Outside Japan, developed countries face the urgent task of slowing the growth of medical expenses associated with aging populations, while emerging countries have a pressing need for medical infrastructure development. Under these circumstances, we anticipate that demand for clinical tests with better quality and greater efficiency will continue to increase and that the clinical testing market will continue to expand. Given these changes in the global operating environment, we will constantly strive to meet needs in our field of expertise. In doing so, we will aim to boost our international competitiveness as a global life science company.

We remain committed to meeting your expectations and justifying your confidence in us, and respectfully ask for your continued support and guidance.

Hiromasa Suzuki, Ph.D.
President & CEO